Dengue virus (DENV) is a mosquito-borne virus that causes severe health problems. An effective tetravalent dengue vaccine candidate that can provide life-long protection simultaneously against all four DENV serotypes is highly anticipated. A better understanding of the antibody response to DENV envelope protein domain III (EDIII) may offer insights into vaccine development. Here, we identified 25 DENV cross-reactive mAbs from immunization with Pichia pastoris-expressed EDIII of a single or all four serotype(s) using a prime-boost protocol, and through pepscan analysis found that 60 % of them (15/25) specifically recognized the same highly conserved linear epitope aa 309-320 of EDIII. All 15 complex-reactive mAbs exhibited significant cross-reactivity with recombinant EDIII from all DENV serotypes and also with C6/36 cells infected with DENV-1, -2, -3 and -4. However, neutralization assays indicated that the majority of these 15 mAbs were either moderately or weakly neutralizing. Through further epitope mapping by yeast surface display, two residues in the AB loop, Q316 and H317, were discovered to be critical. Three-dimensional modelling analysis suggests that this epitope is surface exposed on EDIII but less accessible on the surface of the E protein dimer and trimer, especially on the surface of the mature virion. It is concluded that EDIII as an immunogen may elicit cross-reactive mAbs toward an epitope that is not exposed on the virion surface, therefore contributing inefficiently to the mAbs neutralization potency. Therefore, the prime-boost strategy of EDIII from a single serotype or four serotypes mainly elicited a poorly neutralizing, cross-reactive antibody response to the conserved AB loop of EDIII.
INTRODUCTION
Dengue virus (DENV) has four genetically and antigenically related serotypes (DENV-1, DENV-2, DENV-3 and DENV-4) (Sabin, 1952) . Infection with any one of the four serotypes causes a spectrum of diseases ranging from asymptomatic infection to dengue fever (DF) to dengue haemorrhagic fever (DHF)/dengue shock syndrome (DSS) (Halstead, 2007) . In the absence of effective control measures and licensed vaccines, the magnitude of the dengue epidemic has increased dramatically (Monath, 2007; Thomas & Endy, 2011; Whitehead et al., 2007) and has extended geographically into many previously unaffected areas in recent years (Scott & Morrison, 2010) . The difficulty in eliciting a balanced protective immunity against all four DENV serotypes, combined with the potential for antibody-dependent enhancement (ADE) of DENV infection has greatly hindered vaccine development (Huisman et al., 2009; Murphy & Whitehead, 2011 ). An improved understanding of the humoral immune response against DENV may facilitate the design of antibody-based therapeutics or novel immunization strategies that could elicit balanced immunity against DENV.
The envelope (E) protein, the major surface protein on the virion, contains three distinct domains: I (EDI), II (EDII) and III (EDIII) (Modis et al., 2003) . EDIII is exposed on the surface of the viral particle and contains DENV serotype-specific, subcomplex-specific and complex-specific epitopes as determined previously (Falconar, 1999 (Falconar, , 2008 Gromowski et al., 2008; Lisova et al., 2007; Matsui et al., 2010; Matsui et al., 2009; Pitcher et al., 2012; Roehrig et al., 1998; Sukupolvi-Petty et al., 2007 . The majority of neutralizing mAbs against EDIII of DENV were raised through immunization of mice with DENV-1 or DENV-2 strains and localized to A-strand and/or lateral-ridge epitopes. Several poorly neutralizing, cross-reactive mAbs (5A2-7, 13D4-1 and E111) were also generated with virus immunization, but with an amino acid residue localized to the AB loop of EDIII (Sukupolvi-Petty et al., 2007) . On the other hand, immunizing BALB/c mice with recombinant EDIII (rEDIII) protein of DENV-2 also produced the relatively strongly neutralizing mAb 9F12 that recognizes the A-strand and BCloop epitope (Rajamanonmani et al., 2009 ) and the weakly neutralizing dengue cross-reactive mAb 2H12 localized to the conserved AB loop (Midgley et al., 2012) . Other studies using DENV-isolated EDIII (Zhang et al., 2007) or EDIII fusion protein (Valdés et al., 2009) as immunogens also elicited neutralizing antibodies that were protective in mice or non-human primates against virus challenges. Recent immunization of BALB/c mice with rEDIII having a consensus sequence from all four DENV serotypes successfully induced long-lasting antibody responses and anamnestic neutralizing antibody responses (Chiang et al., 2011) . EDIII has become a region of interest for humoral immune response to DENV and also subunit dengue vaccine candidates.
At the same time, the complexity of humoral immune responses against DENV EDIII is far from being clearly understood. Recent studies using rEDIII and natural EDIII presented on the surface of mutated virions demonstrated that EDIII epitopes are not the main target of human neutralizing antibodies (Wahala et al., 2009 . Nonetheless, anti-EDIII antibodies, if present, may be conducive to reducing viral load (Williams et al., 2012) . Vaccines, if effectively designed and skewed towards advantageous neutralizing epitopes on EDIII, may be effective in protecting against homotypic secondary infection. Therefore, in spite of the discrepancy between murine and human EDIII mAbs, studies of murine EDIIIreactive mAbs may still further enhance the understanding of humoral immunity to DENV.
In this study, using rEDIII proteins from all DENV serotypes as immunogens, we produced a panel of DENV crossreactive mAbs (mostly complex-reactive mAbs) with distinct patterns of inhibitory activity against the four serotypes. Next, the epitopes recognized by these mAbs were determined by pepscan analysis, with their critical residues subsequently defined by yeast surface display of rEDIII variants. Coupled with spatial visualization of epitopes, we found that about 60 % of the cross-reactive mAbs predominantly recognized the same highly conserved DENV-complex epitope localized to the AB loop of EDIII. The mainly poorly complex-reactive mAbs raised against the conserved AB-loop epitope using rEDIII prime-boost regimens add to our understanding of the humoral immune response to EDIII immunization and provide insight into EDIII-based subunit vaccine development.
RESULTS
A complex-specific epitope on EDIII identified by cross-reactive mAbs A large panel of mAbs against EDIII of DENV was produced by immunization with rEDIII of a single serotype or a combination of EDIIIs from all four serotypes. Twenty-five mAbs exhibited cross-reactive binding to rEDIII of all four DENV serotypes and C6/36 cells infected with DENV-1, DENV-2, DENV-3 and DENV-4, respectively. Nearly all of the 25 mAbs showed no cross-reactive binding to C6/36 cells infected with West Nile virus (WNV), Japanese encephalitis virus (JEV) or yellow fever virus (YFV), except for two mAbs (4C58 and 1D51) to WNV (Table 1) .
Next, the panel of cross-reactive mAbs was examined for binding to two sets of overlapping synthetic peptides spanning the entire sequence of the DENV-1 EDIII protein (Fig. S1 ) was used as a negative control. The competition was effective for most of these 15 mAbs, with the corresponding soluble peptide partially or completely inhibiting the binding of the antibodies to solid phase EDIII protein (inhibition ranging from 25.5 to 87.1 %) (Fig. S2 ). Epitope mapping revealed that binding of the 15 mAbs to the continuous aa 309-320 corresponding to peptide 12-4 was specific. In contrast, complex-reactive mAb 2C3 specifically recognized linear epitope peptide aa 361-372 of EDIII from DENV-1 and cross-reactive mAb 4C58 specifically bound to epitope region aa 365-376. The remaining mAbs failed to show binding to any synthetic peptide used in this study (Table 1) and their epitopes were not further identified in this current study.
The cross-reactivity of 15 mAbs (60 % of all cross-reactive mAbs) with EDIII from the four serotypes suggests that this epitope region aa 309-320 is the predominant DENV complex EDIII epitope. It should be pointed out that some of the other peptides tested shared a partial overlap with the 309-320 sequence. mAbs (5E7, 9B3, 2D13, 3A37 and 3E31) exhibited moderate neutralizing activities against nearly all four DENV serotypes with the exception of two mAbs (2D13 against DENV-2 and 3E31 against DENV-3). Another four mAbs (5A1, 5C30, 2C49 and 3A3) showed weak or non-neutralizing activity towards all serotypes. The remaining six mAbs showed either moderate or weak neutralizing activity toward different serotypes. In addition, most of the ten mAbs that showed no binding to epitope aa 309-320 exhibited weak neutralizing activities against DENV, except for mAbs 2D73 and 2B11, which displayed relatively strong neutralizing activities. mAbs 2C3 and 4C58, recognizing regions aa 361-372 and aa 365-376, respectively, showed little neutralizing activity against all four serotypes.
Amino acid conservation and substitution analysis of epitope residues 309-320 on DENV-1 E protein
To further investigate sequence specificity, epitope sequences from different related members of the family Flaviviridae were compared by aligning equivalent aa 309-320 sequences of the EDIII protein from DENV-1, -2, -3 and -4 and WNV, YFV and JEV (Fig. S1 ). This comparison revealed that aa 310-319 sequences are highly conserved among DENV strains of the four DENV serotypes but divergent from those of other flaviviruses (WNV, YFV and JEV). The only variations between the DENV serotypes were at positions 312 (V/I/M) and 313 (A/S). At the time of writing, there were 1772 DENV-1, 1522 DENV-2, 1038 DENV-3 and 392 DENV-4 isolate sequences available in the NCBI Entrez protein database (http://www.ncbi.nlm.nih.gov/protein/) that could be used for sequence alignment analysis. Such alignment revealed that the aa 310-319 determinant was well conserved within isolates of the four DENV serotypes with complete identity among 93.6 (i.e. 1658/1772), 98.7, 99.2 and 98.2 % of the sequences of DENV-1, -2, -3 and -4, respectively. Subsequently, the predominant DENV complex epitope aa 309-320 on the DENV-1 EDIII protein was further investigated by amino acid substitution analysis. Peptides were synthesized corresponding to the aa 309-320 (12-mers, Fig. S1 ) and aa 310-319 (10-mers, Fig. S1 , boxed region) sequences from the E protein of the four DENV serotypes and WNV, YFV and JEV. All 15 mAbs tested for binding to these peptides showed a detectable, and usually strong, reaction with peptide sequences corresponding to the four DENV serotypes but failed to bind any of the peptides with equivalent sequences from WNV, YFV and JEV (Fig. 1) . The specific reactivity of peptides with these mAbs was further confirmed by competitive inhibition experiments. The amino acid substitution analysis corroborated the accuracy of antigenic residues 310-319 as the predominant epitope recognized by DENV-complex-specific mAbs.
Critical residues of complex-reactive mAbs defined by yeast surface display
The critical amino acid residues recognized by mAbs were further analysed by yeast surface displayed EDIII variants.
A panel of EDIII mutants were interrogated for binding to the 15 mAbs localized to the epitope aa 310-319 after being displayed on the surface of yeast (Table S1 and Fig. 2) . Initially, alanine scanning mutagenesis was applied to aa 310-319 of EDIII from DENV-1 Hawaii strain, except for A313 and K310, which were changed into glycine and glutamic acid, respectively. A total of ten single variants were generated and evaluated by flow cytometry after mAb staining. It was found that the binding of 15 mAbs was significantly reduced by mutations at residues Q316 and H317. mAb binding was not appreciably altered with single mutations at each of the other eight positions of the DENV-1 aa 310-319 sequence. Next, we changed individual residues to alanine at positions 316 and 317 of DENV-2, -3 and -4 EDIII, the homologously equivalent positions to DENV-1 EDIII. Additional residue substitutions of I312A, S313A and M312A were also introduced into EDIII of DENV-2, -3 and -4, respectively, considering their variations at these positions.
As illustrated in Table S1 , binding of the first subset of five mAbs (5A12, 5C30, 2C49, 2E14 and 3A3) was moderately (with binding reduction between 50 and 70 %) or significantly (with binding reduction by .70 %) diminished by Q316A and H317A mutants of EDIII from DENV-1, -2, -3 and -4. The binding of the second subset of five mAbs (3B8, 3D3, 5A1, 5E7 and 2D13) was reduced by Q316 and H317 mutations of EDIII from some but not all DENV serotypes. The third subset of four mAbs (9B3, 4A19, 3A37 and 3E31) showed decreased binding exclusively to H317A variants of some or all of DENV serotypes, but not to Q316 variants. A single mAb 2C7 was affected only by an alanine variant of Q316. Thus, residues Q316 and H317 contributed considerably to binding of these complex reactive mAbs to EDIII of DENV.
Structural properties of the aa 309-320 epitope on DENV E protein and the mature virion To visualize spatially how our mAbs recognized DENV EDIII, we mapped residues 309-320 onto the crystal structure of DENV-2 E protein [Protein Data Bank (PDB) codes 1OAN and 1OK8] and pseudoatomic model of mature DENV virion (chimeric tick-borne encephalitis virus E dimer/DENV-4 cryoelectron microscopy pseudoatomic model, PDB code 1K4R) (Kuhn et al., 2002) . Epitope residues mapped onto the mature virion corresponded to the homologously equivalent location of these residues on DENV-2 EDIII. In the entire E protein homodimer, the epitope was sandwiched between EDI and EDIII and was partially masked by these neighbouring domains (Fig. 3a-c) . The epitope aa 309-320 localized to part of the A strand (aa 310-313) and the AB loop (aa 314-319) and appeared to be localized on the exposed surface of the EDIII protein, except for I320, which was inaccessible on the surface of EDIII (Fig. 3d-g ). Of note, Q316 and H317 protruded from the EDIII surface. This epitope was also less accessible on the surface of the E protein trimer (Fig. 3h) . On the mature DENV virion, epitope determinant aa 309-320 was partially occluded, with Q316 and H317 facing the viral membrane. Thus, it is reasonable that sequence 310 KEVAETQHGT 319 of EDIII in DENV-1, and its slight variants in DENV-2, -3 and -4, can elicit antibodies directed against the epitope that is surface exposed on EDIII but less accessible on the mature virion when rEDIII is used as an immunogen. Accordingly, antibodies such as those in our study generally show weak inhibitory activity against DENV.
DISCUSSION
In this study, we produced 25 DENV cross-reactive mAbs, and further characterized their epitopes on EDIII in detail through pepscan analysis, competitive inhibition experiments and amino acid substitution analysis. It was found that 15 of 25 mAbs specifically recognized the same highly conserved epitope, aa 309-320, of EDIII. By using yeast surface display mapping, we determined the critical residues of this epitope recognized by the 15 mAbs. Two residues in the AB loop, Q316 and H317, were discovered to be critical, but the magnitude of significance differed for binding of a given mAb to Q316A and H317A mutants from different serotypes. Specifically, Q316 was only critical for one mAb, 2C7, whilst H317 was the only critical residue for four mAbs (9B3, 4A19, 3A37 and 3E31). Both Q316 and H317 were critical for the remaining ten mAbs. Such disparity in magnitude of binding significance may be due to the discrepant contribution of overall electrostatic and hydrophobic interactions from adjacent residues on the surface of the E protein (Matsui et al., 2009; Volk et al., 2007) , although Q316 and H317 are strictly conserved in EDIII of different serotypes.
All 15 complex-reactive mAbs exhibited significant crossreactivity with rEDIII from all DENV serotypes and also with DENV-1-, DENV-2-, DENV-3-and DENV-4-infected C6/36 cells. However, the majority of them showed only moderate to weak neutralizing activities. Can the discrepancy between significant cross-reactivity and neutralizing capacity exhibited by these 15 mAbs be explained? Further analysis of the aa 310-319 epitope in the crystal structures of the DENV E protein suggested that this antigenic site is surface exposed on EDIII but less accessible on the surface of the E protein dimer and trimer, especially in tightly packed E protein on the surface of the mature virion. Because this epitope faces inward and towards the membrane of the mature DENV virion (Sukupolvi-Petty et al., 2007) , steric hindrance makes it difficult for mAbs recognizing the AB loop to neutralize it efficiently. Isolated rEDIII as immunogen might elicit mAbs to antigenic sites that are exposed on the surface of EDIII but not on the virion surface, therefore contributing inefficiently to neutralization potency against DENV (Pierson & Diamond, 2008) . Moreover, the overall avidities of the antibodies were also shown to be significantly lower after immunization with isolated rEDIII in comparison with inactivated virus (Zlatkovic et al., 2011) . On the other hand, although the AB-loop epitope showed limited accessibility on the virion, dynamic movements on the virion surface at 37 u C (breathing theory) may expose occluded sites transiently (Lok et al., 2008) and allow virus neutralization by these mAbs to partially occluded sites.
In this study, the majority of cross-reactive mAbs localized to the AB loop of EDIII were raised not against virus but against rEDIII of a single serotype or a combination of rEDIIIs from the four serotypes. However, they did not show good neutralizing activities, causing us to reconsider the efficacy of rEDIII subunit immunization regimens used in our study. It seems that immunization using only the EDIII prime-boost strategy cannot elicit adequately protective antibody responses. Very recently, researchers studied immunodominance of antibody responses to recombinant subunit vaccines and inactivated WNV through first priming with virion or E protein followed by EDIII boosting, demonstrating that isolated EDIII was an excellent booster antigen (Zlatkovic et al., 2011) . A similar booster effect of EDIII in terms of neutralizing antibody response to DENV-2 infection in monkeys was also observed (Valdés et al., 2011) . Consequently, in further studies of DENV vaccine candidates, EDIII-based vaccination regimens should be further explored to fully draw on the booster effect of rEDIII.
The conserved DENV-complex-reactive epitope (aa 310-319) reported here was different from several previous related studies. One of them is a study of complexreactive mAb 3A8.1, which showed reactions against DENV-2 synthetic peptides 304 GKFKV/IVKEIA 313 and adjacent 393 KKGSSIGQ/KM 401 (Falconar, 2008) . In another study, five DENV-complex-specific mAbs (GTX29202, GTX77557, MDVP-55A, MA1-27093 and 20-783-74014), with significant variability in their neutralization of DENV1-3, were localized to a single antigenic site on an upper lateral surface of DENV-2 EDIII consisting of residues K310, I312, P332, L389 and W391 (Gromowski et al., 2008) . A series of studies also focused on a complexreactive mAb, 4E11, which neutralizes DENV-1 and -2 strongly and DENV-3 and -4 moderately. The 4E11 epitope was localized originally to the aa 306-314 region (Thullier et al., 2001) and finely mapped to residues 307-312, 387, 389 and 391, with hydrophobic (Leu308, Leu389) and positively charged (Lys307, Lys310) residues constituting hot spots for its binding energy (Cockburn et al., 2012; Lisova et al., 2007) . Although a relatively strongly neutralizing, complex-reactive mAb, 9F12, elicited by BALB/c mice immunization of DENV-2 rEDIII, showed binding to DENV-2 peptide aa 309-318, it localized to an epitope centred at the A strand (residues 305, 307 and 310) and BC loop (residue 330) (Rajamanonmani et al., 2009 ). In these and other studies (Midgley et al., 2012; Pitcher et al., 2012) , K310 and/or I312 have been identified as common critical residues for these complex-reactive mAbs. Nonetheless, complex-reactive mAbs elicited through EDIII immunization in a prime-boost manner in our study are distinct from these well-characterized ones in that K310 and V/I/M312 did not constitute critical determinants for our mAbs. In comparison with these relatively strongly neutralizing mAbs, AB-loop-recognizing mAbs in our study did not demonstrate good neutralizing efficacy in vitro. Similarly, several poorly neutralizing, complexreactive mAbs (5A2-7 and 13D4-1) elicited with virion immunization were mapped to an amino acid residue (H317) in the AB loop (Sukupolvi-Petty et al., 2007) . Another similar dengue cross-reactive mAb, 2H12, generated with a similar immunization scheme to ours was reported recently, which was centred on a core 314 ETQH 317 motif in the AB loop with little or no enhancement of DENV infection (Midgley et al., 2012) . Since the AB-looprecognizing, complex-reactive mAbs reported have not been not fully elucidated, and a large panel of AB-looplocalized, complex-reactive mAbs have been identified here, the protective efficacy and safety issues of such mAbs against infections of the four DENV serotypes requires evaluating in further studies in order to assess the utility of AB-loop-recognizing, complex-reactive mAbs.
METHODS
Ethics statement. The animal study proposal was approved by the Institutional Animal Care and Use Committee (IACUC) of Southern Medical University (SMU) with the permit number SMU IACUC2009-021. All mouse experimental procedures were performed in accordance with Regulations for the Administration of Affairs Concerning Experimental Animals approved by the State Council of the People's Republic of China.
Cells and viruses. Vero-E6 cells (ATCC, Rockwell, MD) and LLC-MK2 (ATCC) were maintained at 37 uC in a 5 % CO 2 incubator in minimal essential medium MEM, Gibco) supplemented with 10 % FBS. The four DENV serotype strains (DENV-1, Hawaii; DENV-2, New Guinea-C; DENV-3, Guanxi-80-2; and DENV-4, H241) used in this study were cultured as described previously (Chen et al., 2010) . The viruses were propagated in C6/36 Aedes albopictus cells (ATCC) in MEM supplemented with 10 % FBS at 28 uC for 3-5 days in the presence of 5 % CO 2 . The infectious titre of each harvested virus pool was determined by a TCID 50 -ELISA in C6/36 cells as previously established by our laboratory . Stocks of virus were prepared at known plaque titres (p.f.u. ml
21
) and kept frozen at 280 uC until use.
Cloning, expression and purification of DENV rEDIII proteins.
DENV rEDIII proteins from the four DENV serotypes were prepared as described previously (Cai et al., 2010) . Briefly, the gene encoding the DENV EDIII from each serotype was cloned into pPIC9 vector (Invitrogen) as a BglII/SacI fragment in frame and downstream of the 66His tag coding sequence. Plasmids were transformed into Pichia pastoris GS115 (Invitrogen). rEDIII protein expression from each DENV serotype was conducted by methanol induction in the exponential phase of P. pastoris growth, and the rEDIII proteins were subsequently purified by Ninitrilotriacetic acid affinity chromatography (Qiagen) according to the manufacturer's instructions.
Production and characterization of mAbs. The production and characterization of mAbs against the rEDIII protein from the four DENV serotypes were performed as follows. BALB/c mice were immunized intraperitoneally with each of the rEDIII proteins alone, or a combination of all four serotypes of rEDIII, mixed with Freund's adjuvant (Sigma-Aldrich). Four boosts of each protein or the mixture were given, and then splenocytes from the immunized mice were harvested and fused with NS-1 myeloma cells. The hybridoma cell lines generated were subsequently screened by indirect ELISA using the rEDIII proteins as coating antigens. The screening was supplemented by an IFA defined in Table 1 that detected mAb binding to C6/36 cells infected with each DENV serotype as described previously (Che et al., 2005; Xu et al., 2006) . Positive hybridoma cells were cloned by limiting dilution. The serotype binding specificity and cross-reactivity of the mAbs were evaluated by ELISA and IFA. Each mAb was isotyped using a commercial isotyping kit (Zymed). The mAbs were purified using protein G column chromatography (Amersham-Pharmacia) according to the manufacturer's instructions.
Peptide synthesis. Two sets of overlapping, biotinylated peptides (16-mer and 12-mer) spanning the entire EDIII sequence from DENV-1 Hawaii strain, with adjacent peptides overlapping by eight residues (Fig. S1) , were designed and synthesized commercially by Huachen Biological Technology (Xi'an, PR China). Synthesized peptides were purified to .90 % as determined by high-performance liquid chromatography. The purity of each peptide was confirmed by laser desorption mass spectrometry. Freeze-dried peptides were dissolved in 100 % DMSO and stored at 280 uC until use.
Epitope mapping using ELISA. The reactivity of mAbs with the overlapping, biotinylated peptides was determined by ELISA as described previously (Chen et al., 2010) . Briefly, 96-well microplates (Costar Corning) were coated with 100 ml streptavidin (5 mg ml 21 ; Sigma-Aldrich) per well in 0.1 M carbonate buffer (pH 9.6) at 4 uC overnight. After washing and blocking, a series of biotinylated peptides at a concentration of 5 mg ml 21 were captured on plates for 2 h at room temperature, followed by sequential incubation with mAb (5 mg ml
) and diluted HRP-conjugated goat anti-mouse IgG (Zymed) for 30 min at room temperature, respectively. Tetramethylbenzidine (KPL) solution was then added and incubated for 10 min after which the reaction was stopped with 0.3 M sulfuric acid. The absorbance was measured at 450 nm in a microplate autoreader (Bio-Tek Instruments). Each sample was tested in duplicate wells. An unrelated mAb was used as control. The reactivity of the mAb with the synthesized peptides was considered positive when the mean absorbance value was 10-fold greater than the mean absorbance value of the mAb control.
Competitive ELISA. The specific reactivity of peptides with corresponding mAbs was confirmed by competitive inhibition experiments as described previously with modifications (Chen et al., 2010) . Briefly, microplates were coated with 100 ml per well of DENV-1 or DENV-2 rEDIII protein at a concentration of 1 mg ml
. Both mAbs and synthetic peptides were diluted in PBS containing 0.1 % BSA. The dilutions of mAbs giving an absorbance at 450 nm of approximately 2.0 were selected for subsequent competitive experiments. Sixty microlitres of mAb at the selected dilution was mixed with an equal volume of soluble synthetic peptides (ranging from 1.0 to 0.063 mg ml 21 ), followed by overnight incubation at 4 uC and 100 ml of this mixture was then transferred into coated microplates, which were incubated for 20 min at 4 uC. After washing, 100 ml per well of diluted HRP-conjugated goat anti-mouse IgG was added and incubated for 30 min at 37 uC. The subsequent procedure for colour development and absorbance determination was the same as that for epitope mapping using ELISA above. Controls were identical except for the omission of synthetic peptides, DENV-1 or DENV-2 rEDIII protein. In vitro neutralization assay using ELISPOT-MNT. ELISPOT-MNT was performed according to methods established in our laboratory (Liu et al., 2012) with modifications. Briefly, LLC-MK2 cells were seeded in 96-well tissue culture plates with a density of 1610 4 cells per well and incubated overnight at 37 uC in a 5 % CO 2 incubator until approximate 90 % confluence. The mAbs were serially diluted twofold from 100 or 200 mg ml 21 in MEM containing 2 % FBS. An equal volume of virus of each serotype (diluted to give about 200 p.f.u. per well) was added to the mAb dilution and mixed well. After incubation at 37 uC for 1 h, the virus-mAb mixture was transferred to the LLC-MK2 cell monolayers in duplicate wells (100 ml per well) and incubated for 1.5 h. Then, the cell monolayers were overlaid with semisolid MEM supplemented with 1 % methylcellulose (Sigma) and 5 % heat-inactivated FBS and then incubated at 37 uC in 5 % CO 2 for 2-3 days. The cells were then fixed for 15 min at 220 uC with acetone/methanol (7 : 3) fixation solution and subjected to an indirect immunostaining assay by incubating with a diluted anti-DENV non-structural protein 1 (NS1) ascitic fluid (5F10A7) that recognizes the four DENV serotypes, followed by HRP-conjugated goat anti-mouse IgG. Spots were then developed with AEC solution (SK4200; Vector Laboratories). The spots were subsequently captured by ELISPOT instrumentation (Cellular Technology) and counted by CTL ImmunoSpot Academic software (version 5.0). The per cent reduction of spots was calculated as follows: % reduction51006[12(mean number of spots for each dilution/mean number of spots for the virus dose control)]. The concentration of mAb was considered to be the neutralizing titre if it showed a 50 % reduction in spot number, compared with an unrelated mAb.
Amino acid substitution analysis of the predominant DENVcomplex epitope on DENV EDIII protein. The predominant DENV-complex epitope aa 309-320 on the DENV-1 EDIII protein was investigated by amino acid substitution analysis. The equivalent 12-mer epitope sequences and conserved 10-mer sequences on the E protein from DENV-1, -2, -3 and -4, WNV, YFV and JEV isolates were synthesized (Fig. S1 ). The consensus sequences for the E protein of related flaviviruses were derived from multiple flavivirus isolates, which were obtained from the NCBI Entrez protein database (http:// www.ncbi.nlm.nih.gov/protein/). E protein sequence alignment was used to identify epitope conservation.
Yeast surface display epitope mapping. The gene encoding the DENV EDIII from each DENV serotype was cloned into PYD1 vector (Invitrogen) as a KpnI/EcoRI fragment, in-frame and downstream fusion to the V5 epitope and 66His tag. Mutation of these recombinant plasmids was introduced with a QuikChange lightning site-directed mutagenesis kit (Stratagene). Plasmids were transformed into Saccharomyces cerevisiae strain EBY100 with the S.c. EasyComp Transformation kit (Invitrogen). Fusion protein expression was induced in tryptophan-free medium with 2 % galactose at 20 uC for 48 h. Yeast cells were harvested, washed with an equal volume PBS and added into a 96-cell culture plate (100 ml per well). mAbs used for staining were diluted at 5 mg ml 21 with PBS supplemented with BSA (1 mg ml 21 ) and added (100 ml per well). After incubation for 30 min on ice, the cells were washed with PBS and stained with 100 ml per well of a 1 : 100-diluted FITC-conjugated goat anti-mouse IgG (Sigma). After fixation with 1 % paraformaldehyde in PBS, stained cells were analysed on a flow cytometer (BD FACScalibur; Becton Dickinson).
Epitope mapping onto the crystal structure of DENV-2 E protein and pseudoatomic structure of the mature virion. The epitope identified was mapped onto the crystal structure of DENV-2 E protein and then docked onto the mature DENV virion. Figures were prepared with the atomic coordinates of the DENV-2 E protein (PDB code 1OAN and 1OK8) and of mature DENV virion (PDB code 1K4R) employing the program Pymol (http://www.pymol.org/) and UCSF Chimera package (http://www.cgl.ucsf.edu/chimera/), respectively.
